Abivax (ABVX.US) Surges Near All-Time High on Eli Lilly Acquisition Speculation

Stock News2025-12-22

On Monday, shares of Abivax S.A. (ABVX.US) surged nearly 15% at the open, approaching its previous all-time high, currently trading at $131.59. The rally follows reports that Eli Lilly has initiated preliminary discussions with French authorities to explore a potential acquisition of the biotech firm.

According to sources, Eli Lilly held initial talks with France's finance ministry in early December to assess whether the proposed takeover would face restrictions under the country's foreign investment review rules. The report also indicated that discussions included the potential involvement of state-backed investor Bpifrance as a minority shareholder.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment